Paul V. Maier

Mr. Maier brings strong senior operational and financial experience, as well as an impressive track record of shaping and expanding life science businesses, to the Biological Dynamics board. He has over 25 years of experience as a senior executive in biotechnology and pharmaceutical companies, where he raised more than $1.5 billion in equity and debt financing and led a number of IPO and M&A transactions.

As Chief Financial Officer of Sequenom, Inc. from November 2009 through June 2014, Mr. Maier was instrumental in raising more than $360 million in equity and debt financing and commercializing Sequenom’s molecular diagnostics segment. He served as Chief Financial Officer at Ligand Pharmaceuticals Inc. from 1992 to 2007 where he helped build the venture-stage company into a commercial, integrated biopharmaceutical organization and ICN Pharmaceuticals (now Valeant Pharmaceuticals International, Inc.) where he served in various senior finance and general management roles.

Mr. Maier currently serves on the Board of Apricus Biosciences, International Stem Cell, MabVax Therapeutics, and Ritter Pharmaceuticals. Mr. Maier received an MBA from Harvard Business School and a BS from Pennsylvania State University.